STAT5A and chronic myelogenous leukemia, BCR-ABL1 positive: These data are in line with earlier reports on up-regulation of STAT5 expression and STAT5 phosphotyrosine-dependent drug effects in kinase inhibitor-resistant and advanced phase CML [46].